Mar 06, 2018 9:25am EST SCYNEXIS Announces Pricing of $30.0 Million Public Offering of Common Stock and Warrants
Feb 01, 2018 8:30am EST SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018
Nov 07, 2017 4:20pm EST SCYNEXIS Reports Third Quarter 2017 Financial Results and Provides Company Update
Oct 05, 2017 8:30am EDT SCYNEXIS Presents New Data Further Supporting SCY-078 as a Potential Treatment for Aspergillus and Candida Infections at IDWeek 2017
